RGIN (Regenicin) Other Current Liabilities: $-0.00 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin Other Current Liabilities?

Regenicin RGIN -99.00% Other Current Liabilities is $-0.00 Mil as of Mar. 2023.

Regenicin's other current liabilities for the quarter that ended in Mar. 2023 was $-0.00 Mil.

Regenicin's quarterly other current liabilities declined from Sep. 2022 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Mar. 2023 ($-0.00 Mil).

Regenicin's annual other current liabilities declined from Sep. 2020 ($0.00 Mil) to Sep. 2021 ($-0.00 Mil) but then increased from Sep. 2021 ($-0.00 Mil) to Sep. 2022 ($0.00 Mil).

Regenicin Other Current Liabilities Related Terms

Regenicin Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Regenicin's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin Other Current Liabilities Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Regenicin Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $-0.00 Mil mean?
Regenicin (RGIN) has a Other Current Liabilities of $-0.00 Mil as of Mar. 2023. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regenicin.
Is Regenicin's Other Current Liabilities too high?
Regenicin's current Other Current Liabilities is $-0.00 Mil.
How does Regenicin's Other Current Liabilities compare to NOVNQ and TMBRQ?
Regenicin's Other Current Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Regenicin. Regenicin's current Other Current Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current Other Current Liabilities of $-0.00 Mil. The current Other Current Liabilities is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Regenicin (RGIN), the current Other Current Liabilities is $-0.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.